Blood Cancer Journal最新文献

{"title":"Dietary patterns among individuals with plasma cell disorders- opportunities for targeted interventions.","authors":"Kadiatou Traore,Francesca Castro,Andriy Derkach,Elan Gorshein,Edith Serrano,Alankrita Taneja,Jorge Arturo Hurtado Martínez,Alexander M Lesokhin,Ana M Sahagun Sanchez Aldana,Patricia Alejandra Flores Pérez,Saad Z Usmani,Jenifer M Ahlstrom,Torin Block,Jay R Hydren,Cynthia A Thomson,Urvi A Shah","doi":"10.1038/s41408-026-01468-0","DOIUrl":"https://doi.org/10.1038/s41408-026-01468-0","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"77 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147518492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disorders.","authors":"Edward Koo,Sarah Albert,Benjamin Patrick,Meriem Henia,Yona Rhiwi,Christopher McCudden,Victor Jimenez Zepeda,Irwindeep Sandhu,Michael Chu,Hira Mian,Alissa Visram","doi":"10.1038/s41408-026-01463-5","DOIUrl":"https://doi.org/10.1038/s41408-026-01463-5","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"105 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147518495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: a single-arm, open-label, phase Ia/Ib study.","authors":"Fan Yang,Rui Liu,Zhonghua Fu,Yuelu Guo,Lixia Ma,Miaomiao Cao,Biping Deng,Alex H Chang,Haifeng Wu,Shilin Gan,Chen Chen,Xiaoyan Ke,Kai Hu","doi":"10.1038/s41408-026-01476-0","DOIUrl":"https://doi.org/10.1038/s41408-026-01476-0","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"310 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147518497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma","authors":"Shaji Kumar, Sundar Jagannath, Katja C. Weisel, Laura Rosiñol, Xavier Leleu, Meletios-Athanasios Dimopoulos, Efstathios Kastritis, David S. Siegel, Jorge Monge, Juan Du, Javier de la Rubia, Pedro Asensi Cantó, Jae Hoon Lee, María-Victoria Mateos, Borja Puertas, Alessandro Gozzetti, Dominik Dytfeld, Enrique M. Ocio, Joan Blade, Shuji Ozaki, Meral Beksac, Fernando Escalante, Madhu Nagaraj, Rafla Hassan, Nicolle Bonar, Paul Spin, Mostafa Shokoohi, Muhaimen Siddiqui, Di Wang, Kevin Hou, Michael E. D. West, Christian Hampp, Jeannette Green, Olivier Humblet, Alexander Breskin, James Harnett, Wenzhen Ge, Rachel E. Sobel, Jessica J. Jalbert, Glenn S. Kroog, Karen Rodriguez Lorenc, Qiufei Ma, Brian G. M. Durie","doi":"10.1038/s41408-026-01466-2","DOIUrl":"https://doi.org/10.1038/s41408-026-01466-2","url":null,"abstract":"LINKER-MM1 (NCT03761108) is a Phase 1/2 study of linvoseltamab, a human BCMA×CD3 bispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM) who are triple-class exposed (TCE) with ≥ 3 prior lines of therapy (3L+), or triple-class refractory (TCR). To contextualize efficacy data from LINKER-MM1, the Phase 2 linvoseltamab 200 mg cohort (N = 105) was compared with an international external control arm (ECA) comprising 203 patients from participating International Myeloma Working Group sites who met LINKER-MM1 eligibility criteria based on chart reviews. The ECA reflected real-world standard-of-care (RW SOC). An independent data review committee assessed data relevance, quality, and cohort comparability, while a separate independent central review committee evaluated response data. Inverse probability of treatment weighting was used to balance baseline characteristics between the linvoseltamab arm and the ECA. Linvoseltamab had a higher objective response rate (weighted odds ratio 3.0 [95% confidence interval (CI): 1.9–4.1]) and longer median progression-free survival (weighted hazard ratio [wHR] 0.33 [95% CI: 0.28–0.40]), time to next treatment (wHR 0.34 [95% CI: 0.29–0.44]), and overall survival (wHR 0.72 [95% CI: 0.58–0.98]) than RW SOC. These findings highlight linvoseltamab’s potential as an effective treatment for 3L+ and TCE/TCR RRMM.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"112 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147506091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imatinib outcomes in chronic myeloid leukemia across diverse health care settings: a systematic review and meta-analysis.","authors":"Marisol Miranda-Galvis,Joshua Wilson,Yazmin Reategui-Almonacid,Lily Johnston,Allison O Taylor,Ramses Sadek,Kellen Tjioe,Jorge E Cortes","doi":"10.1038/s41408-026-01485-z","DOIUrl":"https://doi.org/10.1038/s41408-026-01485-z","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"17 2 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147502403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study","authors":"Matthew Hamby, Brian L. Egleston, Zachary A. K. Frosch, Raphael E. Steiner, Ariela Noy, Veronica Carvajal, Emeline R. Chong, Seda S. Tolu, Gaston Jean-Louis, Jennifer E. Amengual, Romil Patel, Sairah Ahmed, John Sharp, Timothy Voorhees, Robert Baiocchi, Andres Ramirez-Gamero, Jorge J. Castillo, Emily Hamburger, Christopher Dittus, Imran A. Nizamuddin, Neha Mehta-Shah, Nyein Nyein Thaw Dar, Jose Sandoval-Sus, Alexandra E. Rojek, Peter A. Riedell, Niloufer Khan, Alexey Danilov, Vinod Solipuram, Paul G. Rubinstein, Anthony Ariotti, Gita Suneja, Alexander Vartanov, Charles Milrod, Adam J. Olszewski, Gordon Smilnak, Emily Ayers, Sahaj Desai, Joanna M. Rhodes, Gabriella Magarelli, Tatyana Feldman, Meredith Pellon, David M. Aboulafia, William Bae, Carlos Galvez, Vineel Bhatlapenumarthi, Mehdi Hamadani, Stefan K. Barta","doi":"10.1038/s41408-026-01457-3","DOIUrl":"https://doi.org/10.1038/s41408-026-01457-3","url":null,"abstract":"Plasmablastic lymphoma (PBL) is a rare, aggressive AIDS-related lymphoma observed in patients with immunosuppressed states as well as in immunocompetent individuals. We sought to determine survival outcomes, prognostic factors, and optimal treatment regimens in a large, contemporary cohort of patients with PBL in the United States. We performed a multicenter, retrospective cohort study, including 344 patients diagnosed with PBL between 2005 and 2022. Patients were stratified into cohorts according to underlying immune status. Survival outcomes were calculated using Kaplan–Meier statistics, with cohort-specific survival outcomes adjusted using propensity score-based weighting. Factors associated with outcomes were assessed via multivariable models using multiple imputation. The median age at diagnosis was 53 years, most patients were male (n = 270), and many had HIV (n = 164). The median OS was 5.0 years, with a median PFS of 1.4 years. Patients living with HIV had the best outcomes, whereas patients with prior organ transplantation had the worst outcomes. Use of higher intensity chemotherapy regimens and use of a proteasome inhibitor in the frontline setting did not show survival benefit. While there was no clear optimal treatment approach in the frontline setting, the median OS of 5.0 years is dramatically improved compared with historical controls.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"11 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147496789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.","authors":"Cindy Varga,Myra Robinson,James A Davis,Hamza Hashmi,Thomas G Martin,Anupama Kumar,Douglas W Sborov,Charlotte B Wagner,Doris K Hansen,Omar Castaneda Puglianini,Leyla Shune,Evgeunia Bhurtel,Aimaz Afrough,Larry D Anderson,Binod Dhakal,Megan M Herr,Shambavi Richard,Alex Lieberman-Cribbin,Daniel Sherbenou,Peter A Forsberg,Sneha Purvey,Jack Khouri,Yi Lin,Surbhi Sidana,Krina K Patel,Mehmet Kocoglu,Shonali Midha,Christopher J Ferreri","doi":"10.1038/s41408-026-01469-z","DOIUrl":"https://doi.org/10.1038/s41408-026-01469-z","url":null,"abstract":"Prolonged cytopenias are a well-recognized complication following CAR-T therapy. Autologous SCB offers a potential strategy to promote fast hematologic recovery. We conducted a retrospective multi-institutional comparing outcomes of SCB versus supportive care alone in patients with prolonged cytopenias after CAR-T infusion. Patients were included if they received SCB within 1 year following commercial CAR-T between 6/2021 and 3/2024. To identify matched controls, we reviewed 590 CAR-T recipients and selected patients with ANC and platelet thresholds representing the 75th percentile of cytopenia severity in the SCB cohort. Hematologic recovery in the SCB cohort was assessed using CIBMTR engraftment criteria. For the non-SCB (nSCB) group, cell counts were analyzed cross-sectionally at day 60 and 90 post-CAR-T and compared to the SCB cohort with Kruskal-Wallis tests. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier methods. Of 590 patients, 91 patients (15.4%) developed prolonged cytopenias, 39 of whom received SCB. Median CD34+ cell dose was 2.9 million/kg (range: 1.8-23.6) administered at a median of 53 days post-CAR-T (range 24-265). All but one patient (97.4%) in the SCB group achieved hematologic recovery, with median time to recovery of 24 days (range 9-87). No new toxicities attributable to SCB were observed. On day 90 post CAR-T infusion, SCB patients had higher median Hb (10.6 vs. 8.7g/dL, p = 0.002), and platelet counts (135 vs. 35K/L (p < 0.001). After a median follow-up period of 12.6 months in the SCB cohort and 11.6 months in the nSCB arm, the mPFS was 11.0 months and 8.2 months, respectively. Median OS was not reached vs. 12.3 months in the SCB vs. nSCB groups, respectively. Overall, SCB lead to rapid and successful hematologic outcomes in nearly all patients. Compared to matched controls, Hb and platelets were significantly improved by day 90 post-CAR-T infusion.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"52 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147489922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of short-course blinatumomab in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia.","authors":"Ge Liu, Yile Zhou, Yinjun Lou, Hao Ai, Liping Mao, Qian Wang, Hongfei Wu, Hongyan Tong, Xudong Wei, Jie Jin, Huafeng Wang, Qingsong Yin","doi":"10.1038/s41408-026-01460-8","DOIUrl":"10.1038/s41408-026-01460-8","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":11.6,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12999979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147479772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imatinib and nilotinib are equally successful in achieving therapy-free remission.","authors":"Fang Cheng,Yu Wang,Yunfan Yang,Xin Du,Yu Zhu,Jianyu Weng,Na Xu,Jian Huang,Zhenfang Liu,Hongbo Ren,Huifang Zhao,Huanling Zhu,Qian Jiang,Yanli Zhang,Weiming Li","doi":"10.1038/s41408-026-01462-6","DOIUrl":"https://doi.org/10.1038/s41408-026-01462-6","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"233 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147465173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)","authors":"Juying Wei, Qingqing Cai, Liling Zhang, Liqun Zou, Zengjun Li, Keshu Zhou, Huijing Wu, Lihua Qiu, Liping Su, Kaiyang Ding, Hui Zhou, Li Yu, Fei Li, Wenyu Li, Li’e Lin, Qing Xiao, Erhua Wang, Hongmei Jing, Meifang Zheng, Hongyu Zhang, Yuhuan Gao, Da Gao, Lijia Chen, Jie Jin","doi":"10.1038/s41408-026-01452-8","DOIUrl":"https://doi.org/10.1038/s41408-026-01452-8","url":null,"abstract":"Patients with peripheral T cell lymphoma (PTCL) who achieved tumor response with first-line standard therapy were at high risk of disease relapse. We explored golidocitinib (150 mg once daily) as maintenance therapy for this group of patients (JACKPOT26, NCT06511869). This study included two cohorts: patients achieving a complete response (Cohort 1 (CR), N = 30) and a partial response (Cohort 2 (PR), N = 18) during induction stage. All enrolled patients were transplant ineligible or did not have a transplant plan. All dosed patients were included in the efficacy and safety analysis. In Cohort 1, the 24-month disease free survival (DFS) rate was 74.2% with golidocitinib treatment. In nodal subtypes (AITL, NOS, ALK- ALCL), the 24-month DFS rate was 62.7%. In Cohort 2, median progression free survival (PFS) was 17.4 months, and 24-month PFS rate was 48.6%. Nine out of 18 patients with initial PR achieved complete response, leading to a complete response rate of 50.0%, and median duration of response of 23.9 months. The most common ≥grade 3 treatment-related treatment-emergent adverse events (TRAEs) were hematological adverse events in nature, including neutrophil count decreased (47.9%), white blood cell count decreased (31.3%), lymphocyte count decreased (14.6%) and leukopenia (12.5%). The majority of these TRAEs were reversible and clinically manageable. TRAEs leading to treatment interruption and discontinuation occurred in 60.4% and 10% of patients, respectively. No TRAEs leading to fatal outcomes were reported. This study suggests the potential of golidocitinib as maintenance therapy for patients with PTCL.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"36 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147465170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}